Biological differences between fibroblasts derived from peripheral and central areas of keloid tissues.
BACKGROUND
Clinical observations indicate that the bulging and reddish peripheral areas of keloids are more elevated than their central areas. Moreover, the peripheral areas of keloids undergo aggressive growth and invasion into normal skin, beyond the boundaries of the initial wound. The aim of this study was to investigate the biological differences between peripheral and central keloid areas.


METHODS
Six patients suffering from keloids on the anterior chest were selected for this study. Fibroblasts were harvested from both central and peripheral keloid areas. Cell cycle distribution and apoptosis induction were analyzed by flow cytometry and with an antibody to Fas. The expression of apoptosis-related proteins (Fas, Bcl-2, and p53) was measured by flow cytometry.


RESULTS
Fibroblasts derived from both central and peripheral parts of keloids displayed significant resistance to Fas-mediated apoptosis. Analysis of cell cycle distribution indicated that approximately 60 percent of fibroblasts derived from the peripheral parts of keloids were in the proliferative periods of the cell cycle (G2 and S phase). However, the majority of fibroblasts derived from keloid centers were in G0 or G1 phase. Fas and Bcl-2 expression did not differ significantly between the two groups, but p53 expression was much higher in fibroblasts derived from central parts than from peripheral parts.


CONCLUSIONS
It is suggested that differences in cell cycle distribution and p53 protein expression may account for the different growth characteristics of keloid peripheries and centers.
Lu
Feng
F
Guangzhou and Hong Kong, China; and Tokyo, Japan From the Department of Plastic and Reconstructive Surgery, Nanfang Hospital Southern Medical University; Department of Plastic and Reconstructive Surgery, Nippon Medical School; and Department of Community Medicine, University of Hong Kong.
Gao
Jianhua
J
Ogawa
Rei
R
Hyakusoku
Hiko
H
Ou
Chunquan
C
D000328:Adult; D017209:Apoptosis; D002453:Cell Cycle; D049109:Cell Proliferation; D005260:Female; D005347:Fibroblasts / Q000166:cytology; D006801:Humans; D007627:Keloid / Q000473:pathology*; D008297:Male; D008875:Middle Aged
Alhady, S. Keloids in various races. Plast. Reconstr. Surg. 44: 564, 1969.
Ladin, D. A., Garner, W. L., and Smith, D. J. Excessive scarring as a consequence of healing. Wound Repair Regen. 3: 6, 1995.
Nemeth, A. J. Keloids and hypertrophic scars. J. Dermatol. Surg. Oncol. 19: 738, 1993.
Russell, S. B., Trupin, K. M., Rodriguez-Eaton, S., Russell, J. D., and Trupin, J. S. Reduced growth-factor requirement of keloid derived fibroblasts may account for tumor growth. Proc. Natl. Acad. Sci. U.S.A. 85: 587, 1988.
Haisa, M., Okochi, H., and Grotendorst, G. Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J. Invest. Dermatol. 103: 560, 1994.
Ladin, D. A., Hou, A., Patel, D., et al. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen. 6: 28, 1998.
Bao, W., Wang, C., and Zhu, H. Histological and morphological research on different areas of keloid. Chin. J. Plast. Surg. 11: 368, 1995.
Akasaka, Y., Fujita, K., Ishikawa, Y., et al. Detection of apoptosis in keloids and a comparative study on apoptosis between keloids, hypertrophic scars, normal healed flat scars, and dermatofibroma. Wound Repair Regen. 9: 501, 2001.
Chipev, C. C., Simman, R., Hatch, G., et al. Myofibroblast phenotype and apoptosis in keloid and palmar fibroblasts in vitro. Cell Death Differ. 7: 166, 2000.
Rockwell, W. B., Cohen, I. K., and Ehrlich, H. P. Keloids and hypertrophic scars: A comprehensive review. Plast. Reconstr. Surg. 84: 827, 1989.
Ehrlich, H. P., Desmouliere, A., Diegelmann, R. F., et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am. J. Pathol. 145: 105, 1994.
Abergel, R. P., Pizzurro, D., Merker, C. A., et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J. Invest. Dermatol. 84: 384, 1985.
Luo, S., Benathan, M., Raffoul, W., et al. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast. Reconstr. Surg. 107: 87, 2001.
Phan, T. T., Lim, I. J., Chan, S. Y., Tan, E. K., Lee, S. T., and Longaker, M. T. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: Implications for the treatment of excessive scars. J. Trauma 57: 1032, 2004.
Ehrlich, H. P., Desmouliere, A., Diegelmann, R. F., et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am. J. Pathol. 145: 105, 1994.
Lu, F., Gao, J. H., Ogawa, R., et al. Fas mediated apoptotic signal transduction in keloid and hypertrophic scar. Plast. Reconstr. Surg. 119: 1714, 2007.
Perry, D. K., and Hannun, Y. A. The use of diglyceride kinase for quantifying ceramide. Trends Biochem. Sci. 24: 226, 1999.
Hockenbery, D. M., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334, 1990.
Nunez, G., London, L., Hockenbery, D., Alexander, M., McKearn, J. P., and Korsmeyer, S. J. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hematopoietic cell lines. J. Immunol. 144: 3602, 1990.
Itoh, N., Tsujimoto, Y., and Nagata, S. Effect of bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151: 621, 1993.
Shinoura, N., Yoshida, Y., Nishimura, M., et al. Expression level of Bcl-2 determines anti- or proapoptotic function. Cancer Res. 59: 4119, 1999.
Tuan, T. L., and Nichter, S. The molecular basis of keloid and hypertrophic scar formation. Mol. Med. Today 1: 19, 1998.
Chodon, T., Sugihara, T., Igawa, H. H., et al. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am. J. Pathol. 157: 1661, 2000.
Calderon, M., Lawrence, W. T., and Banes, A. J. Increased proliferation of keloid fibroblasts in vitro. J. Surg. Res. 61: 343, 1996.
Nakakao, H., Miyauchi, S., and Miki, Y. Proliferation activity of dermal fibroblasts in keloids and hypertrophic scars. Acta Dermatol. Venereol. (Stockh.) 75: 102, 1995.
Freiberg, R. A., Spencer, D. M., Choate, K. A., et al. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J. Invest. Dermatol. 108: 215, 1997.
Harris, A. L. Mutant p53: The commonest genetic abnormality in human cancer? J. Pathol. 162: 5, 1990.
Lane, D. P., and Benchimol, S. p53: Oncogene or anti-oncogene? Genes Dev. 4: 1, 1990.
Prives, C. How loops, sheets, and helices help us to understand p53. Cell 78: 543, 1994.
Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88: 323, 1997.
Vousden, K. H. p53: Death star. Cell 103: 691, 2000.
Prives, C. Signaling to p53: Breaking the mdm2-p53 circuit. Cell 95: 5, 1998.
Crowe, D. L., and Sinha, U. K. p53 apoptotic response to DNA damage dependent on bcl-2 but not bax in head and neck squamous cell carcinoma lines. Head Neck 28: 15, 2006.